Answers are grounded in this paper and cite their sources.
Patients with glioma demonstrate a high variability of clinical symptoms, in addition to differences in treatment response and survival. Many patients experience epileptic seizures at the onset of the disease, especially with low-grade gliomas, but not all have seizure episodes. A significant portion of patients develop refractory seizures. It is likely that the variability of epileptic symptoms cannot be explained solely by tumor-related factors, but rather reflects a complex interaction between tumor-related factors, environmental factors, and genetic factors. MATERIALS AND METHODS. There is no data on predisposition genes associated with epileptic symptoms in patients with glioma. However, an increasing number of candidate genes have been proposed for other focal epilepsies, such as temporal lobe epilepsy. Some candidate genes associated with focal epilepsy may contribute to the development of epileptic symptoms in patients with glioma. RESULTS. This review presents updated information on studies of genetic polymorphisms and focal epilepsy, as well as described candidate genes for tumor-associated epilepsy based on the assumption that there may be common etiological pathways for glioma development and glioma-associated seizures. CONCLUSION. Genes involved in immune response, synaptic transmission, and cell cycle control are discussed as potential players in the pathogenesis of tumor growth and epileptic symptoms in patients with gliomas.
No takes yet. Share an insight, caveat, or question.
Ulitin et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: